| Literature DB >> 29482635 |
Pengpeng Xia1,2,3, Guomei Quan1,2,3, Yi Yang1,2,3, Jing Zhao1,2,3, Yiting Wang1,2, Mingxu Zhou1,2, Philip R Hardwidge4, Jianzhong Zhu1,2, Siguo Liu5, Guoqiang Zhu6,7,8.
Abstract
The binding of F4+ enterotoxigenic Escherichia coli (ETEC) and the specific receptor on porcine intestinal epithelial cells is the initial step in F4+ ETEC infection. Porcine aminopeptidase N (APN) is a newly discovered receptor for F4 fimbriae that binds directly to FaeG adhesin, which is the major subunit of the F4 fimbriae variants F4ab, F4ac, and F4ad. We used overlapping peptide assays to map the APN-FaeG binding sites, which has facilitated in the identifying the APN-binding amino acids that are located in the same region of FaeG variants, thereby limiting the major binding regions of APN to 13 peptides. To determine the core sequence motif, a panel of FaeG peptides with point mutations and FaeG mutants were constructed. Pull-down and binding reactivity assays using piglet intestines determined that the amino acids G159 of F4ab, N209 and L212 of F4ac, and A200 of F4ad were the critical residues for APN binding of FaeG. We further show using ELISA and confocal microscopy assay that amino acids 553-568, and 652-670 of the APN comprise the linear epitope for FaeG binding in all three F4 fimbriae variants.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29482635 PMCID: PMC5828407 DOI: 10.1186/s13567-018-0519-9
Source DB: PubMed Journal: Vet Res ISSN: 0928-4249 Impact factor: 3.683
Analysis of polypeptide sequences in the positive spots on the APN membrane
| Spots | Sequences |
|---|---|
| 10–11 (28–43 AA) | ALSVVYAQEKNKNAEH |
| 18–20 (52–70 AA) | TITTTAAITLDQSKPWNRY |
| 45–46 (133–148 AA) | VLRGVGDSQVPEIDRT |
| 70–72 (208–223 AA) | QSTDARKSFPCFDEPA |
| 76–78 (226–244 AA) | ATFNITLIHPNNLTALSNM |
| 123–124//126–127 (367–391 AA) | QSSSISNKERVVTVIAHELAHQWFG |
| 146–149 (436–457 AA) | YRVMAVDALASSHPLTTPAEEV |
| 157–161 (469–493 AA) | SISYSKGASVIRMLSNFLTEDLFKE |
| 185–186 (553–568 AA) | KTGNISQKHFLLDSES |
| 194–196 (580–598 AA) | WIVPISSIKNGVMQDHYWL |
| 218–220 (652–670 AA) | VINRAQVIYDSFNLATAHM |
| 281–282 (841–856 AA) | YLGYTLNPDLIRKQDA |
| 301–302 (901–916 AA) | GVTRRFSSEFELQQLE |
Analysis of polypeptide sequences in the positive spots on the FaeG membrane
| Spots | Sequences |
|---|---|
| 50 (148–160 AA) | NASYAGVFGKGGV |
| 59 (175–187 AA) | LRAIFYGGLTTTV |
| 67 (199–217 AA) | AARTELFGSLSRNDILGQI |
| 116 (149–161 AA) | NASYAGVLGRGGV |
| 125 (176–188 AA) | LSSIFYGGLPRGS |
| 133–135 (200–218 AA) | TKLFGSLSRNDILGQIQRV |
| 172 (149–161 AA) | ASYAGALGRGGVT |
| 181 (176–188 AA) | HAIFYGGLPTNVK |
| 189–191 (200–218 AA) | ARTELFGSLSKNDILGQIQ |
Peptides used in this study
| Peptides | Sequences |
|---|---|
| APN 28–43 | FITC-Ahx-ALSVVYAQEKNKNAEH |
| APN 52–70 | FITC-Ahx-TITTTAAITLDQSKPWNRY |
| APN 133–148 | FITC-Ahx-VLRGVGDSQVPEIDRT |
| APN 208–223 | FITC-Ahx-QSTDARKSFPCFDEPA |
| APN 226–244 | FITC-Ahx-ATFNITLIHPNNLTALSNM |
| APN 367–391 | FITC-Ahx-QSSSISNKERVVTVIAHELAHQWFG |
| APN 436–457 | FITC-Ahx-YRVMAVDALASSHPLTTPAEEV |
| APN 469–493 | FITC-Ahx-SISYSKGASVIRMLSNFLTEDLFKE |
| APN 553–568 | FITC-Ahx-KTGNISQKHFLLDSES |
| APN 580–598 | FITC-Ahx-WIVPISSIKNGVMQDHYWL |
| APN 652–670 | FITC-Ahx-VINRAQVIYDSFNLATAHM |
| APN 841–874 | FITC-Ahx-YLGYTLNPDLIRKQDATSTINSIASNVIGQPLAW |
| APN 901–916 | FITC-Ahx-GVTRRFSSEFELQQLE |
| F4ab 148–160 | FITC-Ahx-NASYAGVFGKGGV |
| F4ab 175–187 | FITC-Ahx-LRAIFYGGLTTTV |
| F4ab 199–217 | FITC-Ahx-AARTELFGSLSRNDILGQI |
| F4ac 149–161 | FITC-Ahx-NASYAGVLGRGGV |
| F4ac 176–188 | FITC-Ahx-LSSIFYGGLPRGS |
| F4ac 200–218 | FITC-Ahx-TKLFGSLSRNDILGQIQRV |
| F4ad 149–161 | FITC-Ahx-ASYAGALGRGGVT |
| F4ad 176–188 | FITC-Ahx-HAIFYGGLPTNVK |
| F4ad 200–218 | FITC-Ahx-ARTELFGSLSKNDILGQIQ |
| F4ab 148–160M | FITC-Ahx-NASYAGVFGKG |
| F4ac 200–218 M1 | FITC-Ahx-T |
| F4ac 200–218 M2 | FITC-Ahx-TK |
| F4ac 200–218 M3 | FITC-Ahx-TKLF |
| F4ac 200–218 M4 | FITC-Ahx-TKLFGS |
| F4ac 200–218 M5 | FITC-Ahx-TKLFGSL |
| F4ac 200–218 M6 | FITC-Ahx-TKLFGSLSR |
| F4ac 200–218 M7 | FITC-Ahx-TKLFGSLSRNDI |
| F4ac 200–218 M8 | FITC-Ahx-TKLFGSLSRNDIL |
| F4ac 200–218 M9 | FITC-Ahx-TKLFGSLSRNDILGQIQ |
| F4ad 200–218M | FITC-Ahx- |
The point-mutant amino acid in FaeG peptides are marked in italic.
Figure 1The APN-binding sites in the FaeG protein. A Array of overlapping FaeG peptides from the three variants (F4ab, F4ac and F4ad). Using an overlapping array of 205 peptides, we shifted three amino acids and synthesized them for the FaeG protein (Additional file 1). We detected the relative signal intensity of bound APNs to each position of the membrane by using polyclonal antibodies against the APNs. We used BSA-TBST as a negative control. Based on chemiluminescent signals we analyzed and determined the potential APN-binding sites in the FaeG. The peptide with the strongest intensity was set to 100% and all other spots were normalized to this value. We considered intensity values > 30% to be positive. B Amino acids analysis. The major APN-binding amino acids of the FaeG protein are positioned and marked with a red box. The differences of amino acids in the three serotypes are highlighted in yellow. C Confocal microscopy images. We measured how FaeG peptides interacted with APN using confocal microscopy experiments involving pEC129-APN IPEC-J2 cells and 9 overlapping peptides of FaeG (green, FITC labeled). The peptides of FaeG interacted with APN in pEC129-APN IPEC-J2 cells, the expression of APN in these cells by using polyclonal antibodies against APN and Dylight 549 goat anti-rabbit IgG secondary antibody (red), the interaction between FaeG and the pEC129-APN IPEC-J2 cell as the positive control (P) and the pcDNA™6.2-GW/miR-APN IPEC-J2 cells acted as the negative control (N). D ELISA assays. We coated APN proteins on ELISA plates, used 9 peptides of FaeG and the fusion FaeG proteins from three serotypes to determine the binding sites in FaeG. We repeated each experiment three times. The results shown are mean ± standard deviations (*p < 0.05, **p < 0.01).
Figure 2Analysis of critical amino acids in FaeG for APN binding. A Confocal microscopy images. We measured the critical residues of FaeG for APN binding using pEC129-APN IPEC-J2 cells and the point-mutations in the candidate FaeG peptides using confocal microscopy. B ELISA assays. We used the point-mutations of FaeG peptides to determine the critical residues in APN binding. We repeated the experiments thrice and data are expressed as mean ± standard deviations (*p < 0.05, **p < 0.01). C His pull-down assays. The APN protein is a 2-mer structure, has two bands, and is expressed at 16 °C. We studied the binding between the point-mutations of FaeG and APN proteins using the Pierce™ His protein interaction Pull-down kit. Western blotting by using anti-F4 monoclonal antiserum and anti-APN polyclonal antibodies for detection, the intensity of each band for evaluating the binding activities of APN proteins with FaeG variants.
Figure 3Analysis of peptide and F4 mutant bindings to the proximal jejunal cells. We incubated the bowel segments of the jejunum in peptides and rF4 strains (SE5000 carrying PBR322-faeG of F4ab, F4ac and F4ad). A, B Confocal microscopy images. We measured the binding activities of peptides with amino acid mutations (green, FITC labelled) and F4 FaeG mutants in the proximal jejunum of piglets using confocal microscopy. We tested the F4 strains in these cells by using monoclonal antibody against F4 and anti-mouse Dylight 594 secondary antibody (1:200 dilution, red). Segments with non-binding peptide (NP control) or SE5000 strain as the control.
Figure 4ELISA analysis of FaeG interactions with the truncated APN proteins. We observed the expression of five truncated APN proteins in a prokaryotic system, including APN∆1 (401–963 AA), APN∆2 (1–400 AA), APN∆3 (332–400 AA), APN∆4 (1–331 AA), and APN∆5 (332–963 AA). We analyzed the binding activity between the five purified truncated APN proteins and FaeG using indirect ELISA. pGEX-6p-1 and pet28a (+) as negative controls. We recorded the absorbance at a wavelength of 450 nm, repeated the experiments thrice. The results shown are mean ± standard deviations (*p < 0.05, **p < 0.01).
Figure 5The FaeG-binding sites in the APN protein. A Array of overlapping APN peptides. We used a membrane spotted with peptides (Additional file 2) that spanned the entire amino acid sequence of APN for incubation in either natural F4 fimbrial proteins or fusion FaeG proteins. The image of the membrane shows the reactivity at each spot. The spot with the strongest signal are set the standard (100% intensity), all other intensity values as a relative percentage of this standard. We only considered spots with intensities > 30% as positive. B ELISA assays. We coated APN protein and 13 peptides of the APN on ELISA plates, and then used the coated plates to test the binding activity of the APN with the F4 fimbriae and the FaeG peptides, the APN protein as a positive control. The data presented here are the average of the three experiments and shown as mean ± standard deviations (*p < 0.05, **p < 0.01).